Clinical Trial
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies
Cancer Type
Early Phase Therapy
Protocol Number
202302144
Principal Investigator
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.
Protocol Interventions
Drug: EP0031, Drug: Platinum chemotherapy, Drug: Pemetrexed
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.